Edition:
India

People: Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

127.92USD
10:07pm IST
Change (% chg)

$-6.36 (-4.74%)
Prev Close
$134.28
Open
$133.00
Day's High
$133.00
Day's Low
$127.50
Volume
66,786
Avg. Vol
98,481
52-wk High
$148.97
52-wk Low
$103.00

Smith, David 

Mr. David Ross Smith has been appointed as Chief Financial Officer, Corporate Executive Vice President, of the Company., effective April 26, 2017. He has served as our Corporate Executive Vice President and Chief Financial Officer since August 2015. He joined us as Corporate Vice President, Discovery Services through our acquisition of Argenta and BioFocus from Galapagos NV in March 2014 and was promoted to Corporate Senior Vice President, Global Discovery Services, in October 2014. At Galapagos, he served in various capacities, including as Chief Executive Officer of its Galapagos Services division and as Chief Financial Officer. Mr. Smith served as Chief Financial Officer for Cambridge University Hospitals from 2007 to 2013. Mr. Smith spent eight years at PricewaterhouseCoopers prior to joining AstraZeneca in 1997, where he spent the next nine years in various finance and business roles of increasingly greater responsibility.

Basic Compensation

Total Annual Compensation, USD 533,815
Restricted Stock Award, USD 1,497,540
Long-Term Incentive Plans, USD --
All Other, USD 1,208,590
Fiscal Year Total, USD 3,239,940

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 29,721 1,383,890.00
Name Fiscal Year Total

James Foster

14,450,800

David Smith

3,239,940

David Johst

5,269,400

William Barbo

2,576,390

Birgit Girshick

2,523,360

George Milne

305,049
As Of  29 Dec 2018